Literature DB >> 31662325

Phosphorylation of RAB7 by TBK1/IKKε Regulates Innate Immune Signaling in Triple-Negative Breast Cancer.

Jessica L Ritter1, Zehua Zhu2, Tran C Thai2, Navin R Mahadevan2,3, Philipp Mertins4,5, Erik H Knelson2, Brandon P Piel2, Saemi Han2, Jacob D Jaffe4, Steven A Carr4, David A Barbie2, Thanh U Barbie6,7.   

Abstract

Triple-negative breast cancer (TNBC) is a heterogeneous disease enriched for mutations in PTEN and dysregulation of innate immune signaling. Here, we demonstrate that Rab7, a recently identified substrate of PTEN phosphatase activity, is also a substrate of the innate immune signaling kinases TANK-binding kinase 1 (TBK1)/IκB kinase ε (IKKε) on the same serine-72 (S72) site. An unbiased search for novel TBK1/IKKε substrates using stable isotope labeling with amino acids in cell culture phosphoproteomic analysis identified Rab7-S72 as a top hit. PTEN-null TNBC cells expressing a phosphomimetic version of Rab7-S72 exhibited diffuse cytosolic Rab7 localization and enhanced innate immune signaling, in contrast to a kinase-resistant version, which localized to active puncta that promote lysosomal-mediated stimulator of interferon genes (STING) degradation. Thus, convergence of PTEN loss and TBK1/IKKε activation on Rab7-S72 phosphorylation limited STING turnover and increased downstream production of IRF3 targets including CXCL10, CCL5, and IFNβ. Consistent with this data, PTEN-null TNBC tumors expressed higher levels of STING, and PTEN-null TNBC cell lines were hyperresponsive to STING agonists. Together, these findings begin to uncover how innate immune signaling is dysregulated downstream of TBK1/IKKε in a subset of TNBCs and reveals previously unrecognized cross-talk with STING recycling that may have implications for STING agonism in the clinic. SIGNIFICANCE: These findings identify Rab7 as a substrate for TBK1 for regulation of innate immune signaling, thereby providing important insight for strategies aimed at manipulating the immune response to enhance therapeutic efficacy in TNBC. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31662325      PMCID: PMC6942622          DOI: 10.1158/0008-5472.CAN-19-1310

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Systematic discovery of TLR signaling components delineates viral-sensing circuits.

Authors:  Nicolas Chevrier; Philipp Mertins; Maxim N Artyomov; Alex K Shalek; Matteo Iannacone; Mark F Ciaccio; Irit Gat-Viks; Elena Tonti; Marciela M DeGrace; Karl R Clauser; Manuel Garber; Thomas M Eisenhaure; Nir Yosef; Jacob Robinson; Amy Sutton; Mette S Andersen; David E Root; Ulrich von Andrian; Richard B Jones; Hongkun Park; Steven A Carr; Aviv Regev; Ido Amit; Nir Hacohen
Journal:  Cell       Date:  2011-11-11       Impact factor: 41.582

2.  Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth.

Authors:  Thanh U Barbie; Gabriela Alexe; Amir R Aref; Shunqiang Li; Zehua Zhu; Xiuli Zhang; Yu Imamura; Tran C Thai; Ying Huang; Michaela Bowden; John Herndon; Travis J Cohoon; Timothy Fleming; Pablo Tamayo; Jill P Mesirov; Shuji Ogino; Kwok-Kin Wong; Matthew J Ellis; William C Hahn; David A Barbie; William E Gillanders
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

3.  Biological sequence motif discovery using motif-x.

Authors:  Michael F Chou; Daniel Schwartz
Journal:  Curr Protoc Bioinformatics       Date:  2011-09

4.  The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Authors:  Lisa A Carey; E Claire Dees; Lynda Sawyer; Lisa Gatti; Dominic T Moore; Frances Collichio; David W Ollila; Carolyn I Sartor; Mark L Graham; Charles M Perou
Journal:  Clin Cancer Res       Date:  2007-04-15       Impact factor: 12.531

5.  Comprehensive analysis of PTEN status in breast carcinomas.

Authors:  Natalie Jones; Françoise Bonnet; Sana Sfar; Marie Lafitte; Delfine Lafon; Ghislaine Sierankowski; Véronique Brouste; Guillaume Banneau; Christine Tunon de Lara; Marc Debled; Gaëtan MacGrogan; Michel Longy; Nicolas Sevenet
Journal:  Int J Cancer       Date:  2013-02-12       Impact factor: 7.396

6.  Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy.

Authors:  Sandeep T Koshy; Alexander S Cheung; Luo Gu; Amanda R Graveline; David J Mooney
Journal:  Adv Biosyst       Date:  2017-01-05

7.  Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis.

Authors:  Shuting Li; Yanwei Shen; Mengying Wang; Jiao Yang; Meng Lv; Pan Li; Zheling Chen; Jin Yang
Journal:  Oncotarget       Date:  2017-05-09

8.  Comprehensive molecular portraits of human breast tumours.

Authors: 
Journal:  Nature       Date:  2012-09-23       Impact factor: 49.962

9.  Development of a high-throughput assay for identifying inhibitors of TBK1 and IKKε.

Authors:  Jessica E Hutti; Melissa A Porter; Adam W Cheely; Lewis C Cantley; Xiaodong Wang; Dmitri Kireev; Albert S Baldwin; William P Janzen
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

10.  Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses.

Authors:  Israel Cañadas; Rohit Thummalapalli; Jong Wook Kim; Shunsuke Kitajima; Russell William Jenkins; Camilla Laulund Christensen; Marco Campisi; Yanan Kuang; Yanxi Zhang; Evisa Gjini; Gao Zhang; Tian Tian; Debattama Rai Sen; Diana Miao; Yu Imamura; Tran Thai; Brandon Piel; Hideki Terai; Amir Reza Aref; Timothy Hagan; Shohei Koyama; Masayuki Watanabe; Hideo Baba; Anika Elise Adeni; Christine Anne Lydon; Pablo Tamayo; Zhi Wei; Meenhard Herlyn; Thanh Uyen Barbie; Ravindra Uppaluri; Lynnette Marie Sholl; Ewa Sicinska; Jacob Sands; Scott Rodig; Kwok Kin Wong; Cloud Peter Paweletz; Hideo Watanabe; David Allen Barbie
Journal:  Nat Med       Date:  2018-07-23       Impact factor: 53.440

View more
  7 in total

1.  Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs.

Authors:  Özgün Babur; Alexander R Melrose; Jennifer M Cunliffe; John Klimek; Jiaqing Pang; Anna-Liisa I Sepp; Jevgenia Zilberman-Rudenko; Samuel Tassi Yunga; Tony Zheng; Iván Parra-Izquierdo; Jessica Minnier; Owen J T McCarty; Emek Demir; Ashok P Reddy; Phillip A Wilmarth; Larry L David; Joseph E Aslan
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113

2.  MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer.

Authors:  Shunsuke Kitajima; Tetsuo Tani; Benjamin F Springer; Marco Campisi; Tatsuya Osaki; Koji Haratani; Minyue Chen; Erik H Knelson; Navin R Mahadevan; Jessica Ritter; Ryohei Yoshida; Jens Köhler; Atsuko Ogino; Ryu-Suke Nozawa; Shriram K Sundararaman; Tran C Thai; Mizuki Homme; Brandon Piel; Sophie Kivlehan; Bonje N Obua; Connor Purcell; Mamiko Yajima; Thanh U Barbie; Patrick H Lizotte; Pasi A Jänne; Cloud P Paweletz; Prafulla C Gokhale; David A Barbie
Journal:  Cancer Cell       Date:  2022-09-22       Impact factor: 38.585

Review 3.  Engineering approaches for studying immune-tumor cell interactions and immunotherapy.

Authors:  Sarah E Shelton; Huu Tuan Nguyen; David A Barbie; Roger D Kamm
Journal:  iScience       Date:  2020-12-23

4.  Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis.

Authors:  Chundi Gao; Huayao Li; Cun Liu; Xiaowei Xu; Jing Zhuang; Chao Zhou; Lijuan Liu; Fubin Feng; Changgang Sun
Journal:  Front Immunol       Date:  2021-04-21       Impact factor: 7.561

Review 5.  Mechanisms regulating the sorting of soluble lysosomal proteins.

Authors:  İçten Meraş; Juliette Maes; Stephane Lefrancois
Journal:  Biosci Rep       Date:  2022-05-27       Impact factor: 3.976

Review 6.  Rab GTPases: The principal players in crafting the regulatory landscape of endosomal trafficking.

Authors:  Jing Zhang; Zongyan Jiang; Anbing Shi
Journal:  Comput Struct Biotechnol J       Date:  2022-08-11       Impact factor: 6.155

Review 7.  The Regulation of Rab GTPases by Phosphorylation.

Authors:  Lejia Xu; Yuki Nagai; Yotaro Kajihara; Genta Ito; Taisuke Tomita
Journal:  Biomolecules       Date:  2021-09-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.